Compare IGIC & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGIC | AVTX |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 956.7M |
| IPO Year | 2019 | 2015 |
| Metric | IGIC | AVTX |
|---|---|---|
| Price | $28.69 | $18.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $28.00 | ★ $40.57 |
| AVG Volume (30 Days) | 89.1K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $2.54 | N/A |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $20.82 | $6.21 |
| 52 Week High | $28.84 | $24.27 |
| Indicator | IGIC | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.36 | 51.08 |
| Support Level | $24.51 | $17.32 |
| Resistance Level | $28.84 | $19.06 |
| Average True Range (ATR) | 0.67 | 1.17 |
| MACD | -0.01 | -0.22 |
| Stochastic Oscillator | 93.10 | 18.81 |
International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.